Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01375933 · ClinicalTrials.gov registry record · Phase 3
A Comparability Study of the Phase 3 Lot and a Single Commercial Lot of NicVAX in Healthy Adult Smokers
A Phase 3 study, sponsored by Nabi Biopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 260
- Enrollment target
NCT01375933 is a Phase 3 study that has completed, run by Nabi Biopharmaceuticals. The registered enrollment target is 260 participants.
The verdict
NCT01375933, a Phase 3 study, has completed, sponsored by Nabi Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 260 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the comparability of the phase 3 lot and a single commercial lot of NicVAX in healthy smokers.
Interventions
- BIOLOGICAL NicVAX Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2011-05 |
| Est. Completion | 2011-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01375933
The ClinicalTrials.gov registry entry for NCT01375933 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nabi Biopharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NicVAX Vaccine is the first listed.
NCT01375933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01375933 about?
NCT01375933 is a clinical study titled "A Comparability Study of the Phase 3 Lot and a Single Commercial Lot of NicVAX in Healthy Adult Smokers". The purpose of this study is to assess the comparability of the phase 3 lot and a single commercial lot of NicVAX in healthy smokers.
What is the current status of trial NCT01375933?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 260 participants. The study started on 2011-05. Estimated completion is 2011-10.
What interventions are being tested in trial NCT01375933?
The interventions under investigation include: NicVAX Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01375933?
This trial is sponsored by Nabi Biopharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.